Fundraising FoxThe Column Group — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US
C. Alexander Kamb(Director)inJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)in
Board seatDavid V. Goeddel· per SEC Form D
Co-investorsCasdin CapitalMana VenturesNextech InvestVida VenturesSamsara BioCapital
Surrozen develops multifunctional biologic therapies that selectively activate Wnt signaling to address ophthalmic diseases with unmet medical needs.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Anna Berkenblit(Director)Harold Varmus(Director)
BoardDavid Goeddel(Director)inCraig Parker(Executive Officer, Director)
Board seatDavid V. GoeddelTim Kutzkey· per SEC Form D
Co-investors5AM VenturesAccess BiotechnologyHorizons Ventures
Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.
BiotechDeep TechHealthtechBoston, US
Andrea Ballabio(Founder)Beth Levine(Founder)Herbert Virgin(Founder)James Hurley(Founder)in
Co-investorsAstellas Venture Management LLCThird Rock VenturesEisai Innovation, Inc.Ono Venture Investment, Inc.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.